Small molecule · Inhibitor of AP2-associated kinase 1 (AAK1) · developed by Satellos Bioscience
SAT-3247 is an oral tablet that selectively inhibits AAK1, a kinase, to restore asymmetric satellite cell division. This is intended to increase muscle progenitor cell production, improve muscle regeneration and enhance muscle function. It is being studied in Duchenne muscular dystrophy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07287189 | Phase 2 | Duchenne Muscular Dystrophy | Active not recruiting | MSLE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
DMDDuchenneDuchenne Muscular DystrophyMuscular DystrophiesNeuromuscular Diseases
Updated Oct 25, 2026. Something wrong or missing? Report it on the MSLE page.
See MSLE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MSLE catalysts and pipeline →